Patents Assigned to DENALI THERAPEUTICS, INC.
  • COMPOUNDS, COMPOSITIONS, AND METHODS
    Publication number: 20230227436
    Abstract: The present disclosure relates generally to LRRK2 inhibitors, or a pharmaceutically acceptable salt, deuterated analog, prodrug, tautomer, stereoisomer, or mixture of stereoisomers thereof, and methods of making and using thereof.
    Type: Application
    Filed: January 19, 2023
    Publication date: July 20, 2023
    Applicant: DENALI THERAPEUTICS INC.
    Inventors: Javier de Vicente Fidalgo, Anthony A. Estrada, Jianwen A. Feng, Joseph P. Lyssikatos, Zachary K. Sweeney
  • ENGINEERED ANTI-HER2 BISPECIFIC PROTEINS
    Publication number: 20230192887
    Abstract: In one aspect, bispecific proteins having the ability to specifically bind to both subdomain II of human HER2 and subdomain IV of human HER2 are provided. In another aspect, methods of treating a cancer or treating brain metastasis of a cancer using a bispecific protein that specifically binds to subdomain II and subdomain IV of human HER2 are provided.
    Type: Application
    Filed: August 11, 2022
    Publication date: June 22, 2023
    Applicant: Denali Therapeutics Inc.
    Inventors: Gunasekaran Kannan, Do Jin Kim, Wanda Kwan, Raymond Ka Hang Tong
  • Phospho-Rab antibodies, assays and methods of use thereof
    Patent number: 11661461
    Abstract: In one aspect, antibodies that specifically bind to a phosphorylated Rab protein are provided. In some embodiments, the antibody is a monoclonal antibody that specifically binds to a phosphorylated human Rab10 protein and recognizes an epitope within or comprising the sequence AGQERFH(pT)ITTSYYR (SEQ ID NO:123). In some embodiments, the antibody is a monoclonal antibody that specifically binds to a phosphorylated human Rab8a protein and recognizes an epitope within or comprising the sequence QERFR(pT)ITTAY (SEQ ID NO:125). Methods and materials for detecting LRRK2 and Rab protein are also provided.
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: May 30, 2023
    Assignee: Denali Therapeutics Inc.
    Inventors: Jason C. Dugas, Anastasia Henry, Sarah Huntwork-Rodriguez, Michael T. Maloney, Nathan Moerke, Ella Negrou, Xiang Wang
  • Progranulin variants
    Patent number: 11643446
    Abstract: Provided herein are progranulin variants and fusion proteins that comprise a progranulin variant and an Fc polypeptide. Methods of using such proteins to treat progranulin-associated disorders (e.g., a neurodegenerative disease, such as frontotemporal dementia (FTD)) are also provided herein.
    Type: Grant
    Filed: March 17, 2022
    Date of Patent: May 9, 2023
    Assignee: Denali Therapeutics Inc.
    Inventors: Gerald Maxwell Cherf, Gunasekaran Kannan, Katrina W. Lexa, Ray L. Y. Low, Rachel Prorok, Ankita Srivastava
  • METHODS FOR TREATING DYSREGULATED LIPID METABOLISM
    Publication number: 20230132366
    Abstract: Certain embodiments described herein provide a method for treating dysregulated lipid metabolism and/or inflammation in a mammal in need thereof, comprising administering to the mammal an effective amount of an agonist anti-triggering receptor expressed on myeloid cells 2 (TREM2) antibody.
    Type: Application
    Filed: November 26, 2019
    Publication date: April 27, 2023
    Applicant: DENALI THERAPEUTICS INC.
    Inventors: Giuseppe ASTARITA, Gilbert DI PAOLO, Kai Lin LIN, Kathryn M. MONROE, Alicia A. NUGENT, Bettina VAN LENGERICH
  • Transferrin receptor transgenic models
    Patent number: 11612150
    Abstract: In some aspects, the present invention provides chimeric transferrin receptor (TfR) polynucleotides and polypeptides. In other aspects, this invention provides chimeric TfR transgenic animal models and methods of using the animal models to identify therapeutics that can cross the blood-brain barrier.
    Type: Grant
    Filed: October 19, 2018
    Date of Patent: March 28, 2023
    Assignee: Denali Therapeutics Inc.
    Inventors: Mark S. Dennis, Adam P. Silverman, Joy Yu Zuchero
  • METHODS FOR THE TREATMENT OF HUNTER SYNDROME
    Publication number: 20230092681
    Abstract: Certain embodiments provide a method of treating Hunter syndrome in a subject in need thereof, comprising administering to the subject a therapeutically effective dose of a pharmaceutical composition comprising an ETV:IDS protein.
    Type: Application
    Filed: February 5, 2021
    Publication date: March 23, 2023
    Applicant: DENALI THERAPEUTICS INC.
    Inventors: Annie ARGUELLO, Heather CAHAN, Vinay M. DARYANI, Anita GROVER, Matthew D. TROYER
  • FUSION PROTEINS COMPRISING SULFOGLUCOSAMINE SULFOHYDROLASE ENZYMES AND METHODS THEREOF
    Publication number: 20230062800
    Abstract: Provided herein are proteins, which are capable of being transported across the blood-brain barrier (BBB) and comprise sulfoglucosamine sulfohydrolase (SGSH) enzyme-Fc fusion polypeptides. Certain embodiments also provide methods of using such proteins to treat Sanfilippo syndrome A.
    Type: Application
    Filed: June 30, 2022
    Publication date: March 2, 2023
    Applicant: DENALI THERAPEUTICS INC.
    Inventors: Tina GIESE, Gunasekaran KANNAN, Mihalis KARIOLIS, Cathal MAHON
  • Compounds, compositions, and methods
    Patent number: 11591316
    Abstract: The present disclosure relates generally to LRRK2 inhibitors, or a pharmaceutically acceptable salt, deuterated analog, prodrug, tautomer, stereoisomer, or mixture of stereoisomers thereof, and methods of making and using thereof.
    Type: Grant
    Filed: August 13, 2021
    Date of Patent: February 28, 2023
    Assignee: Denali Therapeutics Inc.
    Inventors: Javier de Vicente Fidalgo, Anthony A. Estrada, Jianwen A. Feng, Joseph P. Lyssikatos, Zachary K. Sweeney
  • Compounds, Compositions and Methods
    Publication number: 20230043400
    Abstract: The present disclosure relates generally to compounds and compositions, and their use as kinase inhibitors.
    Type: Application
    Filed: February 25, 2021
    Publication date: February 9, 2023
    Applicant: Denali Therapeutics Inc.
    Inventors: Anthony A. Estrada, Jianwen A. Feng, Brian Fox, Colin Phillip Leslie, Joseph P. Lyssikatos, Alfonso Pozzan, Zachary K. Sweeney, Javier de Vicente Fidalgo
  • MODIFIED RELEASE FORMULATION OF A PYRIMIDINYLAMINO-PYRAZOLE COMPOUND, AND METHODS OF TREATMENT
    Publication number: 20220249479
    Abstract: The present disclosure relates to modified release formulations of 2-methyl-2-(3-methyl-4-(4-(methylamino)-5-(trifluoromethyl)pyrimidin-2-ylamino)-IH-pyrazol-1-propanenitrile or solvates, tautomers, and pharmaceutically acceptable salts thereof, and methods of treatment with the modified release formulations.
    Type: Application
    Filed: May 29, 2020
    Publication date: August 11, 2022
    Applicant: DENALI THERAPEUTICS INC.
    Inventors: Harish RAVIVARAPU, Travis REMARCHUK, Anantha SUDHAKAR, Bradley K. WONG
  • PROGRANULIN VARIANTS
    Publication number: 20220220172
    Abstract: Provided herein are progranulin variants and fusion proteins that comprise a progranulin variant and an Fc polypeptide. Methods of using such proteins to treat progranulin-associated disorders (e.g., a neurodegenerative disease, such as frontotemporal dementia (FTD)) are also provided herein.
    Type: Application
    Filed: March 18, 2022
    Publication date: July 14, 2022
    Applicant: Denali Therapeutics Inc.
    Inventors: Gerald Maxwell Cherf, Gunasekaran Kannan, Katrina W. Lexa, Ray L.Y. Low, Rachel Prorok, Ankita Srivastava
  • COMPOUNDS, COMPOSITIONS, AND METHODS
    Publication number: 20220220094
    Abstract: The present disclosure relates generally to LRRK2 inhibitors, or a pharmaceutically acceptable salt, isotopically enriched analog, tautomer, stereoisomer, mixture of stereoisomers, prodrug, or pharmaceutical composition thereof, and methods of making and using thereof.
    Type: Application
    Filed: April 10, 2020
    Publication date: July 14, 2022
    Applicant: DENALI THERAPEUTICS INC.
    Inventors: Javier de Vicente Fidalgo, Anthony A. Estrada, Jianwen A. Feng, Zachary K. Sweeney
  • PROGRANULIN VARIANTS
    Publication number: 20220213155
    Abstract: Provided herein are progranulin variants and fusion proteins that comprise a progranulin variant and an Fc polypeptide. Methods of using such proteins to treat progranulin-associated disorders (e.g., a neurodegenerative disease, such as frontotemporal dementia (FTD)) are also provided herein.
    Type: Application
    Filed: March 17, 2022
    Publication date: July 7, 2022
    Applicant: Denali Therapeutics Inc.
    Inventors: Gerald Maxwell Cherf, Gunasekaran Kannan, Katrina W. Lexa, Ray L.Y. Low, Rachel Prorok, Ankita Srivastava
  • Anti-Tau antibodies and methods of use thereof
    Patent number: 11370832
    Abstract: In one aspect, antibodies that specifically bind to a human Tau protein are provided. In some embodiments, an anti-Tau antibody recognizes an epitope within residues 111-125 of full-length human Tau, an epitope within residues 251-270 and/or residues 346-360 of full-length human Tau, or an epitope within residues 186-205 of full-length human Tau. In some embodiments, an anti-Tau antibody specifically binds to phosphorylated human Tau, unphosphorylated human Tau, and/or multiple splice isoforms of human Tau. An anti-Tau antibody disclosed herein may also include one or two modified Fc polypeptides.
    Type: Grant
    Filed: August 16, 2019
    Date of Patent: June 28, 2022
    Assignee: Denali Therapeutics Inc.
    Inventors: Xiaocheng Chen, Mark S. Dennis, Lesley Ann Kane, Do Jin Kim, Joseph W. Lewcock, Suresh Poda, Rishi Rakhit, Rinkan Shukla, Adam P. Silverman
  • FORMULATIONS OF PROTEIN MOLECULES COMPRISING IDURONATE 2-SULFATASE
    Publication number: 20220184186
    Abstract: Certain embodiments provide a pharmaceutical composition comprising: a protein molecule comprising an ERT enzyme-Fc fusion polypeptide and a modified Fc polypeptide; a buffer; an isotonicity agent; a surfactant; and a stabilizer; wherein the pH of the pharmaceutical composition is about 5.5 to 7.0, as well as methods of use thereof.
    Type: Application
    Filed: April 3, 2020
    Publication date: June 16, 2022
    Applicant: DENALI THERAPEUTICS INC.
    Inventors: Dana ANDERSEN, Adam CATHERMAN, Tina GIESE, Gunasekaran KANNAN, Mihalis KARIOLIS, Cathal MAHON, Ankit PATEL
  • COMPOUNDS, COMPOSITIONS AND METHODS
    Publication number: 20220153728
    Abstract: The present disclosure relates generally to LRRK2 inhibitors, or a pharmaceutically acceptable salt, deuterated analog, prodrug, tautomer, stereoisomer, or mixture of stereoisomers thereof, and methods of making and using thereof.
    Type: Application
    Filed: February 1, 2022
    Publication date: May 19, 2022
    Applicant: DENALI THERAPEUTICS INC.
    Inventors: Anthony A. Estrada, Jianwen A. Feng, Javier De Vicente Fidalgo, Zachary K. Sweeney
  • COMPOUNDS, COMPOSITIONS, AND METHODS
    Publication number: 20220135546
    Abstract: The present disclosure relates generally to LRRK2 inhibitors, or a pharmaceutically acceptable salt, deuterated analog, prodrug, tautomer, stereoisomer, or mixture of stereoisomers thereof, and methods of making and using thereof.
    Type: Application
    Filed: August 13, 2021
    Publication date: May 5, 2022
    Applicant: DENALI THERAPEUTICS INC.
    Inventors: Javier de Vicente Fidalgo, Anthony A. Estrada, Jianwen A. Feng, Joseph P. Lyssikatos, Zachary K. Sweeney
  • COMPOUND, COMPOSITIONS, AND METHODS
    Publication number: 20220119371
    Abstract: Compounds having activity as LRRK2 inhibitors are disclosed. The compounds are of formula (I) including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Application
    Filed: December 29, 2021
    Publication date: April 21, 2022
    Applicant: DENALI THERAPEUTICS INC.
    Inventors: Anthony A. Estrada, Jianwen A. Feng, Joseph P. Lyssikatos, Zachary K. Sweeney, Javier de Vicente Fidalgo
  • ANTI-TREM2 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20220119522
    Abstract: In one aspect, antibodies that specifically bind to a human triggering receptor expressed on myeloid cells 2 (TREM2) protein are provided. In some embodiments, the antibody decreases levels of soluble TREM2 (sTREM2). In some embodiments, the antibody enhances TREM2 activity.
    Type: Application
    Filed: August 16, 2021
    Publication date: April 21, 2022
    Applicant: Denali Therapeutics Inc.
    Inventors: Mark S. Dennis, Sherie Duncan, Kathleen Lisaingo, Kathryn M. Monroe, Joshua I. Park, Rachel Prorok, Ju Shi, Ankita Srivastava, Bettina Van Lengerich, Riley Walsh